Evidence map›Paper›PMID 36215276›Full record

ArticleThe oncologist2022

Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices.

Wei-Li Ma, Dwan-Ying Chang, Ching-Hung Lin, Kao-Lang Liu, Po-Chin Liang, Huang-Chun Lien, Chan-Chuan Hu, Ling-Yun Huang, Yi-Chun Yeh, Yen-Shen Lu

Open access · goldAbstract read
In one paragraph

Article in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. [Research progress on pseudocirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Wei-Li MaDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-6840-2976
Dwan-Ying ChangDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Ching-Hung LinDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-2403-4056
Kao-Lang LiuDepartment of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan.
Po-Chin LiangDepartment of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan.
Huang-Chun LienDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Chan-Chuan HuDepartment of Medical Research and Education, National Taiwan University Cancer Center, Taipei, Taiwan.
Ling-Yun HuangClinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan.
Yi-Chun YehDepartment of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
Yen-Shen LuDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0001-7461-1291
National Taiwan University Hospital · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPseudocirrhosis is an imaging finding of malignancies with liver metastasis with or without clinical liver cirrhosis-related portal hypertension (pHTN). This study defined evident pHTN by the presence of esophageal or gastric varices and compared patients' outcomes of metastatic breast cancer with imaging-diagnosed pseudocirrhosis with or without varices.

methodsThe medical records from patients with metastatic breast cancer and pseudocirrhosis between 2005 and 2017 were retrospectively analyzed. Survival outcomes were compared based on endoscopic evidence of esophageal or gastric varices.

resultsAmong 106 patients with pseudocirrhosis, 33 (31%) had de novo stage IV disease, and 66 (62%) had hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Eighty-one (76%) had initial metastases in both hepatic lobes, and 32 (30%) had esophageal or gastric varices. The median overall survival (OS) was 5 and 13 months in patients with and without varices (P = .002). The median OS in patients with HER2-positive, HR-positive/HER2-negative, and triple-negative subtype was 16, 9, and 2 months, respectively (P = .001). Patients with varices usually had cirrhotic complications, including gastrointestinal bleeding, hyperbilirubinemia, hyperammonemia, and coagulopathy. Despite their challenging clinical conditions, 7 patients with varices had OS exceeding 1 year. In multivariate analysis, evident varices (P = .007) and triple-negative subtype (P = .013) were associated with poor OS.

conclusionsPatients with pseudocirrhosis and evident varices had a significantly shorter median OS, and were usually associated with clinical cirrhosis-related complications. To maximize OS, early identification and meticulous supportive care are warranted.

Indexed as

Breast NeoplasmsEsophageal and Gastric VaricesFemaleHumansRetrospective Studieslivermetastatic breast cancerportal hypertensionpseudocirrhosis

Identifiers

PMID36215276
PMCPMC10249426
OpenAlexW4304114148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.